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Abstract
D-tocopheryl polyethylene glycol succinate (Vitamin E TPGS) has been 
approved as a safe pharmaceutical adjuvant by FDA, and several drug delivery 
systems (DDS) based on TPGS have been developed. TPGS properties as a P-gp 
inhibitor, solubilizer/absorption and permeation enhancer in drug delivery and 
TPGS-related formulations such as nanocrystals, nanosuspensions, tablets/solid 
dispersions, vaccine system adjuvant, nutritional supplement, film plasticizer, 
anticancer reagent, and so on, are discussed in this review. Consequenly, TPGS can 
inhibit ATP-dependent P-glycoprotein activity and act as a potent excipient that 
promotes the efficiency of delivery and the therapeutic effect of drugs. Inhibition of 
P-gp occurs through mitochondria-dependent inhibition of the P-gp pump. Many 
of the latest studies address the use of TPGS for many poorly water-soluble or per-
meable drugs in the manufacture of nanodrugs or other formulations. In addition, it 
has been reported that TPGS shows a robust improvement in chylomicron secretion 
at low concentrations and improves intestinal lymphatic transport, which would 
also boost the potential of drug absorption. It also indicates that there are still many 
problems facing clinical translation of TPGS-based nanomedicines, requiring a 
more deep evaluation of TPGS properties and a future-based delivery method.
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1. Introduction
An alternative to PEG, D-alpha-tocopheryl polyethylene glycol 1000 succinate 
(TPGS), is an amphiphilic macromolecule, a water-soluble natural vitamin E 
derivative. It is a powerful nanotechnological emulsifier for biomedical applica-
tions. TPGS co-administration can enhance solubility, cellular internalization, 
inhibit the multi-drug efflux transport mechanism mediated by P-glycoprotein, 
which increase the oral bioavailability of different anticancer drugsVitamin E TPGS 
is a water-soluble derivative of natural vitamin E derived from vitamin E succinate 
esterification with polyethylene glycol (PEG) 1000 [1]. Because of its superior 
water solubility and biocompatibility, PEG is the most widely applied hydrophilic 
segment. In order for the molecular weight to be higher than the hydrophobic core, 
the micellar shell is usually chosen to shape the molecule. In micelles, these findings 
have critical micellar concentrations in the micromolar range, and are often smaller 
than 100 nm. Vitamin E TPGS is a nonionic surfactant with a molecular weight rate 
of 1513 g.mol-1 and a lipophilic alkyl tail and hydrophilic polar head amphiphilic 
frame that is fully soluble in water. It is constant, range of pH 4.6–7.6 less than 12 
percent break down when kept for three months in neutral aqueous buffer. The 
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Vitamin E TPGS safety has been notify at the oral LD50 is >7 000 mg/kg for adult 
male rats [2, 3]. In addition, a variety of compounds such as cyclosporines, taxans, 
hormones and antibiotics, both water-soluble and water-insoluble, can be solubi-
lized by vitamin E TPGS [3]. Vitamin E TPGS could act as a P-gp inhibitor. It has the 
ability to inhibit the action of P-gp, stronger than other non-ionic surfactants such 
as Tween 80, Pluronics and Cremophor. It has been used in various formulations/
applications, such as producing nano suspensions [4], self-microemulsifying [3], 
nutrition supplement formulates nanoparticles, dependent prodrug, and strong 
dispersion/tablet, vaccine system adjuvant [5–8].
Vitamin E TPGS is widely used, with several functions, such as: hydrophobic 
drug vehicle, to amelorate ocular permeability and provide ocular retention. TPGS 
is used as a vitamin E accessory or to treat vitamin E insufficiency in people who 
are unable to consume lipids due to specific illness [9]. Tocofersolan oral solu-
tion has been confirmed by the European Medicines Agency in the treatment of 
vitamin E deficiency due to digestive malabsorption in pediatric patients, inborn 
misery or hereditary chronic cholestasis [10]. Tocofersolan is also used as an 
antioxidant and anti-inflammatory in cosmetics and pharmaceutical products. In 
different parts of health, especially in neuroprotection, dermal, cardiovascular, 
and bone health, these crucial benefits of vitamin E are valuable. In nanoformula-
tions involving solid-lipid nanoparticles, nanoemulsions, nanostructured lipid 
carriers, and polymeric nanoparticles, several TPGS formalizations have recently 
shown favorable results in improving the efficacy and bioavailability of many 
drugs [11]. Vitamin E has a prospective ban on metabolic syndrome and cardio-
vascular diseases (CVDs) [12]. These influences are mediated via inhibition of 
the HMG-CoA reductase enzyme thus antioxidant, anti-inflammatory activity, 
and block expression of adhesion molecules. Diabetic rat studies have confirmed 
that supplementation with TPGS decreases fasting blood glucose, oxidative stress 
and strengthens the integrity of vascular walls that help to resolve atherosclerotic 
lesions [13, 14]. Additionally, in dermatology, vitamin E is often used as a protec-
tive antioxidant and ultraviolet (UV) radiation that suits photoprotection and 
retards skin aging through its ability to improve collagen synthesis and avoid col-
lagen dissolution [15, 16]. In addition to adding, TPGS has beneficial anti-cancer 
properties, such as preventing cancer cell proliferation, prohibiting angiogenesis, 
altering growth factors, encouraging cell cycle arrest, and inducing apoptosis [17]. 
The physicochemical and biological properties of TPGS relevant to drug delivery 
applications are generally described in Figure 1 as well as, the role of TPGS in 
enhancing the bioavailability and targetability of anticancer drugs has been 
highlighted in this review.
Figure 1. 
Various pharmacological properties of vitamin E.
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1.1 Vitamin E TPGS, an amphiphilic polymer
E TPGS is a water-miscible form of vitamin E, which approved by the FDA and 
commonly used in drug delivery systems as a safe adjuvant. TPGS’s biological and 
physicochemical properties provide several advantages for its drug delivery applica-
tions such as high biocompatibility, drug solubility enhancement, drug permeation 
improvement, and selective antitumor activity [18].
1.2 Structure and properties
Vitamin E TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate or 
TPGS) is a water-soluble derivative of natural vitamin E, formed together with 
polyethylene glycol 1000 by esterification of d-alpha-tocopheryl polyethylene glycol 
succinate. Furthermore, TPGS is a macromolecule consisting of a lipophilic alkyl 
tail and a hydrophilic polar head which has amphiphilic properties (see Figure 2).
Vitamin E TPGS is an active solubilizer of various compounds that are water-
soluble and insoluble in water, such as steroids, antibiotics, cyclosporins, taxanes, 
etc. [21]. TPGS vitamin E could function as a P-gp inhibitor with a higher capacity 
than other non-ionic surfactants, such as Tween 80, Pluronics and Cremophor EL, 
to inhibit P-gp activity [21].
2. Absorption/bioavailability enhancer
Several studies indicated that the increased bioavailability was due to micelle 
formation improving solubility, while others showed that P-glycoprotein (P-gp) 
inhibition contributes to increased permeability support [22, 23]. Although several 
instances of TPGS use are poorly water-soluble drugs, there are also examples of the 
use of TPGS with water-soluble poorly permeable drugs. Many studies have been 
done to evaluate the mechanism by which TPGS improve bioavailability, many of 
these suggestions to micelle formation and through enhancing permeability across 
cell membranes by inhibition of multidrug efflux pump P-with regard to oral 
Figure 2. 
Chemical structure of vitamin E TPGS. The lipophile to hydrophile equilibrium of the TPGS is an unique 
amphiphilic structure. Consequently, it is a waxy solid with an air-stable melting point of about 41° C, ranging 
from yellow to light brown in color. In nature, it is bulky and has a broader surface area, so it is considered 
the ideal emulsifier and strong solubilizer [19]. The chemical structure of TPGS used in many formulations/
applications shown in Figure 2, such as: 1. Improving drug bioavailability, 2. Properties of surfactants which 
improve the solubilization of drugs poorly water soluble, 3. Stabilizer of amorphous drug forms 4. Inhibiting 
the efflux of P-glycoprotein which improves drug permeability, 5. Emulsion vehicle, 6. The active ingredient 
in self-emulsifying formulations, 7. Minimize drug damage to dermal tissues, 8. Carrier for wound care and 
therapy, 9. Vitamin E water-soluble source, 10. Fabrication nanosuspensions, 11. Self-microemulsifying and 
solid tablet/dispersion 12. Vaccine device Adjuvant, 13. Boost of nutrition, 14. Nano-particles formulation,  
15. Micelles, 16. Liposomes, 17. Based prodrug [20].
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deliveryBy beneficially emulsifying and solubilizing the medication in the finished 
dosage type and by considering a self-emulsifying drug delivery mechanism in the 
stomach that may be due to TPGS, TPGS increases the permeability of a drug across 
cell membranes by inhibiting P-glycoprotein and thus facilitates the absorption of a 
drug over the intestinal wall and into the cell membranes. Furthermore, TPGS is a 
more potent P-gp inhibitor than many associated excipients with surfactant proper-
ties, such as Pluronic P85 cremophor EL, Tween 80, and PEG 300, Figure 3. Yu et al 
[24] The solubility of amprenavir was amended in the existence of vitamin E-TPGS 
out of micelle solubilization. Vitamin E-TPGS prevent the efflux system and boost 
the permeability of amprenavir [24]. Chiefly, vitamin E-TPGS promotes the absorp-
tion flux of the drug by increasing its solubility and permeability.
2.1 TPGS properties in drug delivery systems
The water-miscible type of vitamin E, TPGS, consists of a hydrophilic chain of 
PEG connected to the hydrophobic portion of vitamin E. According to a particular 
amphiphilic structure, it shows wonderful drug delivery capability. Further research 
has shown that TPGS has great potential for P-gp inhibition and selective anticancer 
outcomes to resolve MDR tumors [25]. TPGS can be readily conjugated with polymers 
or therapeutic agents to form TPGS based polymers Figure 4. It is possible to further 
self-assemble the resulting composition into nanoparticles, in order to form nanofor-
mulations, unmodified TPGS can also participate with other active compounds. After 
cell internalization, in response to the unique intracellular environment (e.g. pH, GSH 
and ROS), the nanoparticles can be degraded to release the therapeutic agents and 
TPGS [26]. The drugs can be easily pumped out into the extracellular environment 
without P-gp inhibition [27]. Dissociated TPGS can bind to mitochondrial respiratory 
complex II and cause mitochondrial dysfunction, resulting in decreased potential 
for mitochondrial membranes and increased generation of ROS cell apoptosis with 
decreased activation a level of P-gp ATP [18]. Besides, to further resolve MDR, TPGS 
can also inhibit the substrate-induced activity of ATPase. The intracellular concentra-
tion of therapeutic drugs can be greatly improved with P-gp inhibition. Meanwhile to 
enhance cell apoptosis, TPGS can inhibit Bcl-2 and Survivin (Figure 1) [28].
Figure 3. 
The applications of vitamin E TPGS in drug delivery [20].Polyethyeleneglycol (PEG).
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3. TPGS as a surfactant
Poor water solubility and/or poor permeability remain the great snag for 
maximum activity of therapeutic drugs [3, 29, 30]. In drug delivery, TPGS can be 
used as a solubilizer, permeation enhancer, diffusion, and emulsifier as well as as 
Figure 4. 
Nanoprecipation methoed for preparing TPGS coated PLGA polymer nanoparticles. PLGA (Polylactic co 
glycolic acid).
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a surface stabilizer. It has been commonly used for many poorly water-soluble or 
permeable drugs in the manufacture of nanodrugs or other formulations, mainly 
for class II and IV Biopharmaceutical Classification System (BCS) drugs [31]. In 
addition, it has been clearly documented that TPGS shows a good boost in low 
concentration chylomicron secretion and promotes intestinal lymphatic transport 
[32], which would further improve the drug absorption potential. As a surfactant, 
TPGS shows a remarkable ability to surpass drug absorption through different 
biological barriers. For example, TPGS is used to generate repaglinide nanocrystals 
to increase the saturation solubility of the oral bioavailability reference drug from 
15-to 25.7-fold [33]. In addition, TPGS can increase the penetration of drugs in 
colonic tissue [34]. Importantly, in the production of nanoparticles with small 
particle size, high drug encapsulation strength, and quick drug release, TPGS may 
also act as a pore-forming agent [35]. Furthermore, TPGS can be used as an emulsi-
fier or surface stabilizer for drug formulations since the hydrophobic portion can 
trap hydrophobic drugs and the formulations can be stabilized by the hydrophilic 
portion.
4. Role of TPGS to control cancer cell
TPGS acts selectively as an anticancer TPGS by synergistic antitumor action, 
can induce apoptosis and demonstrate selective cytotoxic activity against in vitro 
cancer cells that can be combined or loaded with chemotherapeutic drugs to resolve 
adverse effects and potentiate therapeutic efficiency. The response of cancer cells 
and normal immortalized breast cells after TPGS therapy is of significant value. Via 
activating the apoptotic signaling pathways, TPGS can induce G1/S cell cycle arrest 
in breast cancer cell culture [28]. Jurkat clone E6–1 cells will induce apoptosis on T 
cell acute lymphocytic leukemia. Apoptosis has been demonstrated by encourag-
ing cell cycle arrest, accelerating nuclear DNA fragmentation, and reducing the 
possible mitochondrial membrane after treatment with TPGS [36]. The selective 
processes for TPGS-mediated apoptosis cancer cells are sophisticated and can be 
described as follows:-
4.1 α-Ractive oxygen species stimulation
Alpha-tocopheryl succinate (alpha-TOS), through the eradication and suppres-
sion of mitochondrial respiratory complex II, would induce cancer cell apoptosis 
[37]. ROS formation can be activated by the subsidiary electron transfer chain 
defect. The increase of intracellular ROS, an apoptosis mediator, can induce pro-
tein, lipid, and enzyme oxidation and DNA damage that leads to cell destruction 
[38]. This mechanism is also associated with the selective activity of anticancer, as 
tumor cells may be more sensitive than healthy cells to ROS. Anti-apoptotic protein 
downregulation TPGS could inhibit the phosphorylation of protein kinase B and 
then downregulate Survivin, which represents anti-apoptotic proteins, and Bcl-2, 
which can induce caspase-3 and caspase-7 potential for programmed cell death 
dependent on caspase [39]. At the same time, caspase-independent programmed 
cell death and G1/S phase cell cycle arrest also happened. In general, TPGS also 
appears to be harmful to malignant cells, such as lung adenocarcinoma and breast 
cancer, through mitochondria-associated apoptosis and ROS [40], generation [41]. 
Recently reported that TPGS induces OS apoptosis in acute lymphoblastic leukemia 
involving a cell death signaling pathway. However, no information is ready to limit 
whether TPGS might eliminate Neuroblastoma tumor cells [42].
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4.2 DNA damage
TPGS can induce both caspase-dependent caspase and -independent DNA 
damage [43]. The ability of vitamin E to trigger caspase-independent programmed 
cell death could indeed be effective in prostate cancer chemotherapy as it can block 
tumor resistance usually associated with the use of classical chemotherapeutic 
drugs that trigger programmed cell death dependent on caspase [44].
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Doxorubicin (DOX), Paclitaxel (PTX), docetaxel (DTX), 5-fluorouracil (5-FU), lipopolysaccharide (LPS).
Table 1. 
The P-gp inhibition effect of MDR in the drug delivery system is mainly discussed in this section.
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4.3 TPGS based prodrugs
A prodrug is a drug class with minimal to no therapeutic activity and can be sub-
mitted to a set of in vivo metabolism to generate parental drugs [45]. It is designed 
to improve the concentration of pharmacokinetic (PK), pharmaceutical and 
pharmacodynamic (PD) products, such as boosting drug solubility, safety, bioavail-
ability, permeability, efficiency of treatment and reducing adverse effects. The 
prodrug can be classified purely into prodrug and precursor prodrug carrier-setup. 
The carrier-based prodrug, which is synthesized by a temporal connector merely 
conjugating polymer with the drug, can easily collect itself into nanoformulation as 
well as provide great potential for clinical recruitment [46]. The data summerized 
in Table 1 explain the role of TPGS and prodrug payload on several types of tumor 
model with their application.
Over one natural system, stimulus-responsive prodrugs based on TPGS can be 
prepared to recognize optimum cancer therapy [54].
5. Effect of TPGS on malaria
Malaria is one of the main worldwide infectious diseases. In 2015 only, 212 mil-
lion cases of malaria and 430,000 malaria deaths were reported [55]. Plasmodium 
falciparum and P. vivax respect the majority of the etiology of malaria and the vast 
majority of deaths are due to P. falciparum malaria [56]. P. falciparum infections 
are most likely to develop into severe symptoms such as intense anemia, difficult 
respiration and cerebral malaria (CM) among human-adapted Plasmodium spp. 
infections [57]. Several studies show that alpha-TOS inhibits the mitochondrial 
complex II in ROS generation, which induces selective apoptosis in several types of 
malignant cells, although it is mainly non-toxic to healthy cells [44, 58]. In addition, 
cells that lack the potency of the mitochondrial respiratory chain are resistant to 
alpha-TOS toxicity. Nevertheless the mechanism for alpha-TOS to remain obscure 
is selectively effective on cancer cells. The effect of plasmodium parasites that are 
highly susceptible to oxidative stress is doubtful for alpha-TOS. Alpha-Tocopheryl 
succinate-inhibits the development of cerebral malaria in mice [59].
TPGS is a suitable candidate for safe new anti-malarial drug, This research has 
shown that TPGS therapy of malaria, survival rates in mice infected with two para-
sites have been significantly elevated. Similarly, the severity of Evans blue staining 
on the brains taken from mice treated with TPGS was lower than the remedy not 
received by mice. This indicates that TPGS should prohibit the collapse of the BBB 
and the development of cerebral malaria. These data suggest that the potential 
candidate for malaria treatment drugs could be vitamin E-TPGS. Higher levels 
have been found after TPGS administration particularly in mitochondria, plasma 
membranes, and hepatocyte nuclei [60]. The majority of alpha-TOS in hepatocytes 
that can hydrolyze the esterified forms of vitamin E which may sooner or later 
hydrolyzed into alptocopherol [61]. In addition, the amount of alpha-tocopherol is 
comparatively lower in erythrocytes than in other organs such as the liver, kidney, 
or heart. Although the amount of TPGS is 10 times greater in well-vascularized 
normal organs such as the liver and kidney than that found in tumors, Alpha-TOS 
damages tumor cells but not normal cells, indicating that selective anti-tumor activ-
ity of alpha-TOS is not correlated with differences in levels in tissue accumulation 
[62]. Artemisinin and its derivatives that interact with iron to create free radicals 
are well known as anti-malarial drugs which reported that have growth inhibitory 
effects on cancer cells and non-toxicity to normal cells in both in vitro and in vivo 
studies. Cancer cells typically contain higher free iron levels than normal cells In the 
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form of heme molecules, plasmodium parasites often contain a high amount of Fe2+ 
[63]. A time-dependent stimulation of mitochondrial hydrogen peroxide develop-
ment was triggered by the adding of alpha-TOS to cultured cancer cells.
6. TPGS based polymers in drug delivery
TPGS-based polymers are extensively used in the drug delivery system, which 
can enhance the drug’s encapsulation efficiency, intracellular cell uptake and 
therapeutic efficacy in vitro and in vivo [64]. The first synthesized PLA-TPGS drug 
delivery copolymer which produces significant antitumor efficiency. A set of TPGS-
based polymers including poly(lactic-co-glycolic acid) (PLGA)-TPGS. [40] hyal-
uronic acid (HA)-TPGS, poly(beta-amino ester) (PBAE)-TPGS, polycaprolactone 
(PCL)-TPGS and chitosan-TPGS have obtained significant benefits and have been 
synthesized for medical applications [65, 66]. PLGA, a biocompatible polymer, is 
non-immunogenic and can be metabolized in nature to non-toxic products. PLGA 
is however, hydrophobic and can be quickly filtered and captured by the reticuloen-
dothelial system in the liver. With the assistance of the TPGS, these shortages could 
be masterfully prevented. As a polymeric matrix for nanoparticles, the PLGA-TPGS 
polymer can be used to deliver therapeutic agents that can achieve high drug 
encapsulation performance, sustained-release action, and improved therapeutic 
effects [67].
To enhance the pharmacological effects, PLGA-TPGS nanoparticles can be 
prepared to encapsulate these. Emodin, Tanshinone was loaded through qurecetin-
loading nanoparticles of PLGA-TPGS, resulting in improved antitumor activity for 
liver cancer [68, 69]. Gao et al. combined separately loaded heparin sodium and 
oleanolic acid with PLGA-TPGS nanoparticles indicating synergistic antitumor 
activity in the HCa-F liver cancer cells [70]. Star-shaped polymer-based drug car-
riers have lower hydrodynamic radius, minimize solution viscosity, increase drug 
loading content and increase drug encapsulation performance in comparison to the 
linear polymers of the same molar mass [71], in comparison to linear PLGA-b-TPGS 
copolymer-based nanoparticles, doxitaxil-loaded-PLGA-b-TPGS block copolymer 
nanoparticles present perfect cellular uptake efficiency and sufficient antitumor 
efficacy. Table 2 showed that effect of polymers types and drugs loading on tumer 
model with their application.
6.1 TPGS based formulations to improve drug oral bioavailability
Oral administration is an appealing drug delivery way owing to the simplicity, 
convenience, high patient compliance, perfect for chronic therapy, and minimize 
costs for industry and physicians [77]. In addition various inherent challenges, such 
as reduced permeability through the gastrointestinal tract, low water solubility, 
enzyme hydrolysis and first-pass elimination, which lead to lower absorption and 
bioavailability, continue to limit effective drug delivery [78]. P-gp and CYP3A4 sub-
strates are the majority of Class IV biopharmaceutical classification system drugs, 
resulting in low permeability and existing class metabolism [79]. TPGS-based 
formulations have several advantages in enhancing the bioavailability of orally 
administered drugsIn addition, for the sake of a nonionic surfactant, TPGS can 
improve drug solubility. On the other hand, due to the P-gp inhibition effect, TPGS 
can enhance drug permeability [72]. Furthermore, the ability to boost drug stability 
by inhibiting CYP3A4 and CYP2C9-mediated metabolism was confirmed by TPGS 
[80]. TPGS has shown little inhibition effect on CYP3A activity in other studies 
[81], which may be linked to dosage [82]. Nanocrystals, nanosuspensions, the 
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self-emulsifying/micro emulsifying drug delivery mechanism (SEDDS/SMEDDS), 
solid dispersions/tablet, solid lipid nanoparticles (SLNs), liposomes and micelles 
and emulsified TPGS nanoparticles are included in the TPGS formulations.
6.2 TPGS based formulations to improve drug oral bioavailability
Oral administration is an appealing drug delivery way owing to the simplicity, 
convenience, high patient compliance, perfect for chronic therapy and minimize 
costs for industry and physicians [83, 84]. Furthermore, there are still different 
inherent challenges hampering the effective delivery of drugs, such as limited 
permeability through the gastrointestinal tract, low water solubility, hydrolysis by 
enzymes and first pass elimination, which lead to lower absorption and bioavail-
ability [85]. In fact, a majority of biopharmaceutics classification system class IV 
drugs are substrates of P-gp and CYP3A4, result in poor permeability and extensive 
pre-systemic metabolism [86]. TPGS-based formulations have numerous advan-
tages to improve bioavailability of orally administered drugs. In addition to, as 
TPGS has ability to increase drug solubility due to a nonionic surfactant. On the 
other aspect, TPGS can enhance drug permeation due to the P-gp inhibition effect. 
Furthermore, TPGS has been confirmed with the ability to improve drug stabil-
ity by inhibiting the CYP3A4 and CYP2C9-mediated metabolism [87]. In other 
studies, TPGS showed little inhibition effect on CYP3A activity [88, 89], which 
may be related to the dosage [90]. The TPGS formulations involve nanocrystals, 
nanosupensions, self-emulsifying/microemulsifying drug delivery system (SEDDS/
SMEDDS), solid dispersions/tablet, solid lipid nanoparticles (SLNs), liposomes and 
micelles, TPGS emulsified nanoparticles and so on.
Vitamin E (TPGS) is a lipid-soluble organic compound and usually present in 
the cell membranes. This vitamin has robust antioxidant properties and inhibits the 
Polymer Payload Tumor model Application Ref
Chitosan-g-TPGS DOX Hepatoma 2.4-fold AUC, 2.0-fold 
MRT vs. free drug after oral 
administration
[72]
iRGD-TPGS PTX Resistant lung 
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Significant drug accumulation, 
downregulation of Survivin 
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4-arm-PEG-TPGS PTX Hepatoma Significant in vivo antitumor 
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mice
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PBAE-g-TPGS PTX Resistant breast 
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PTX, targeted drug delivery to 
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ADR tumor inhibition
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Inspired by the use of PLA-TPGS copolymer loading antitumer and their effects.
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lipid peroxidation formd by the free hydroxyl and superoxide radicals [91]. This 
vitamin save the cell membrane of sperm cells from damages of ROS. In vitro studies 
have demonstrated that the utilize of vitamin E -TPGS amilorate the availability, 
motility and fertilizing capacity of sperm in the egg penetration of animals. Likwise, 
in vivo research, supplementation of vitamin E was found to be effective in reduc-
ing the number and motility of sperms caused by reactive oxygen species (ROS)
[92]. The administration of this vitamin during oral route has significant advantages 
influnce on the motility of sperms through the depression synthesis of malondialde-
hyde (MDA), which is known as the final part of lipid peroxidation [93].
The deficiency of vitamin E may spoil the reproductive organs like harm in the 
spermatogenesis, testicular dysfunction and seminiferous tubules shrinkage. The 
utilize of this vitamin boost the functions of testes in the form of excess in the weight 
ofepididymis and testes. In addition, the antioxidants properties of TPGS, endog-
enous, antioxidant enzymes like superoxide dismutase (SOD), and glutathione per-
oxidase are augmented due to the use of this vitamin [94]. This imbalance between 
the endogenous antioxidants and oxidative stress results in a situation of infertility in 
males. Antioxidants play an essential role in eliminating these free radicals. Vitamin E 
is one of the better antioxidants for the sweep of oxidative stress in the male repro-
ductive system. Its use raise functions of the reproductive system and its effecacy. 
The lack of TPGS result in the declination of germinal epithelium and Leydig cells in 
seminiferous tubules.
The use of selenium and vitamin E posses synergistic effects on the male 
reproductive system. More than 25% of males defeat to output functional sperms 
for effective insemination [94]. The over production of ROS is the main cause of 
infertility by damaging the genetic material and enzymes activities of [13]. ROS can 
be harmful or benefit according to their site as well as level of production [95]. The 
sperm have the capability to move after the transit stay in epididymis. They demand 
some physiological processes such as capacitation takes place during the female 
reproductive tract to fertilize the egg, through this physiological event the suf-
fcint amount of ROS is produced [96]. In the ROS, superoxide is count as the most 
harmful agent. The male germ cells are susceptible to ROS due to a higher amount 
of polyunsaturated fatty acids within the cell membrane and cytoplasm [97].
Vitamin E is considered an essential portion of antioxidants in sperm [38] and 
acts as a substantial protection to minimize the production of reactive oxygen 
species [30]. Spermatozoa demand the ROS for natural functions like acrosome 
functions, capacitation, and incorporation of spermatozoa through the operation 
of fertilization [43]. But the production of an excess quantity of ROS leads to lipid 
peroxidation in the membrane of sperm [43, 44]. Vitamin E prevents the produc-
tion of ROS in the sperm membrane during the various motility processes due to 
lipid-soluble [43]. In addition to scavenging of ROS, this vitamin has the capacity 
to conserve the primary reproductive organs and accessory reproductive organs in 
males. Feeding of vitamin E sbsquent metabolism and absorption of vitamin reduc-
tion of ROS in blood result in Increase in semen quality parameters and testosterone 
rise in antioxidants enzymes (Superoxide dismutase, glutathion peroxidase). 
Glutathion peroxidase (GPx) is considered as the asignificant antioxidant and mini-
mize the amount of lipid peroxidation. This enzyme act potentiating to vitamin E as 
a oppsite agent for hydrogen peroxide [98].
7. Osteoartharitis
Osteoarthritis (OA) of the knee is a major reason of chronic, incompetence in 
elderly people, the pathogenesis of this disease until now not clear understood [60]. 
Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects
12
Recent guide demonstrates that oxidative stress, the event wherein oxidant levels 
overtake those of antioxidative agents, is one of the motives factors of OA [99–101]. 
ROS including oxidants that are generated under the physiological situation in the 
human body and controlled by cellular antioxidants, lead to functional and struc-
tural damage of cartilage cells. Several report studies of the relationship between 
oxidative stress and OA have been undertaken. The elevation nitrite, a stable dete-
rioration biochemical marker of the being of nitric oxide, has been confirmed in the 
plasma and synovial fluid of patients with OA [102]. Vitamin E, a dietary antioxi-
dant capable of augmenting the total cellular antioxidant ability, reportedly has 
a positive influence on the symptomatic therapy of arthritis [103, 104]. However, 
there is very little proof from high quality trials that vitamin E modifies oxidative 
markers and clinical signs in people with knee osteoarthritis [28, 105]. This is the 
primary randomized controlled trial that converge on the influence of vitamin E in 
end stage knee OA and entirely estimate clinical symptoms, biochemistry and his-
tology results. We hypothesized that a sustained peroid of vitamin E administration 
will reduce the oxidative stress, inflammatory process and ameloriate symptoms in 
patients with end stage knee OA.
8. Conclusions
In this chapter, we summarized the feature and recent advancements of TPGS 
in drug delivery and pharmaceutical application. TPGS has been approved by FDA 
as a secure pharmaceutical adjuvant with top biocompatibility. In addition to TPGS 
can serve as an effective P-gp inhibitor for overcoming MDR. TPGS oneself can 
be active as an anticancer agent with selective toxicity to tumor cells. TPGS can be 
easily combined with nanotechnology to develop nanomedicines, which has been 
shown as a promising strategy in cancer treatment with increased solubility and 
stability of therapeutic agents, improved PK/PD, enhanced treatment efficiency, 
and minimize side effects. Furthermore, the impact of TPGS on the immune 
system, TPGS can be used as an adjuvant in vaccine development. As to TPGS based 
formulations, the limitations to realize the precise stimuli-responsive property and 
deep penetration of nanoformulations in the tumor microenvironment still remain 
as obstacles for the widespread application of these nanomedicines. However, the 
production of TPGS nanomedicines is yet on a laboratory scale and the progress in 
developing novel nanomedicines is comparatively slow, which hinders the effective 
clinical translation of TPGS based nanomedicines.
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